The Occurrence of Metabolic Risk Factors Stratified by Psoriasis Severity: A Swedish Population-Based Matched Cohort Study

Figures & data

Table 1 Baseline Characteristics of Adult Patients with Psoriasis by Severity of the Disease

	Mild Psoriasis		Moderate Psoriasis		Severe Psoriasis
	Pso Group	Non-Pso Group	Pso Group	Non-Pso Group	Pso Group	Non-Pso Group
Total number	29434	244479	14903	123305	3252	27015
Sex
Men (%)	15241 (51.8%)	127374 (52.1%)	7785 (52.2%)	64823 (52.6%)	1764 (54.2%)	14734 (54.5%)
Number of individuals in each age category at index
≤30	2978 (10.1%)	26775 (11%)	983 (6.6%)	8848 (7.2%)	310 (9.5%)	2810 (10.4%)
30–40	3823 (13%)	33051 (13.5%)	1767 (11.9%)	15276 (12.4%)	624 (19.2%)	5285 (19.6%)
40–50	4630 (15.7%)	39246 (16.1%)	2710 (18.2%)	22945 (18.6%)	762 (23.4%)	6404 (23.7%)
50–60	6001 (20.4%)	48452 (19.8%)	3558 (23.9%)	28727 (23.3%)	800 (24.6%)	6451 (23.9%)
60–70	6664 (22.6%)	52697 (21.6%)	3596 (24.1%)	28455 (23.1%)	575 (17.7%)	4575 (16.9%)
≥70	5338 (18.1%)	44258 (18.1%)	2289 (15.4%)	19054 (15.5%)	181 (5.6%)	1490 (5.5%)
Median age (IQR)	55.8 (41.3–66.5)	55 (40.4–66.3)	55.9 (43.8–65.3)	55.3 (43.1–65.2)	49.2 (38.4–59.1)	48.5 (38–58.7)
Calendar year at index
2007	11682 (39.7%)	96663 (39.5%)	5367 (36%)	44246 (35.9%)	1035 (31.8%)	8581 (31.8%)
2008	4130 (14%)	34275 (14%)	1617 (10.9%)	13325 (10.8%)	367 (11.3%)	3012 (11.1%)
2009	3398 (11.5%)	28241 (11.6%)	1494 (10%)	12313 (10%)	328 (10.1%)	2746 (10.2%)
2010	3080 (10.5%)	25478 (10.4%)	1476 (9.9%)	12268 (9.9%)	304 (9.3%)	2479 (9.2%)
2011	2568 (8.7%)	21366 (8.7%)	1633 (11%)	13516 (11%)	362 (11.1%)	3063 (11.3%)
2012	2403 (8.2%)	20073 (8.2%)	1662 (11.2%)	13795 (11.2%)	403 (12.4%)	3363 (12.4%)
2013	2173 (7.4%)	18383 (7.5%)	1654 (11.1%)	13842 (11.2%)	453 (13.9%)	3771 (14%)

Table 2 Hazard Ratio (HR) and 95% Confidence Interval of Metabolic Risk Factors Among Patients with Psoriasis Compared to Individuals Without Psoriasis

	Mild Psoriasis			Moderate Psoriasis			Severe Psoriasis
	No.	HR	95% CI	No.	HR	95% CI	No.	HR	95% CI
Hypertension
All individuals
Average	255058	1.29	1.27–1.32	128335	1.35	1.32–1.38	28699	1.73	1.64–1.82
Individuals without hypertension prior to index
Average	191957	1.27	1.23–1.30	96402	1.39	1.33–1.44	23619	1.73	1.60–1.87
Individuals with hypertension prior to index
Average	63101	0.95	0.93–0.97	31933	0.92	0.89–0.95	5080	0.91	0.85–0.98
Hypercholesterolemia
All individuals
Average	255088	1.34	1.31–1.38	128346	1.32	1.28–1.36	28699	1.58	1.47–1.7
Individuals without hypercholesterolemia prior to index
Average	223081	1.34	1.3–1.39	112222	1.43	1.37–1.5	26228	1.91	1.74–2.08
Individuals with hypercholesterolemia prior to index
Average	32007	0.85	0.83–0.88	16124	0.84	0.81–0.88	2471	0.78	0.7–0.88
Diabetes
All individuals
Average	255080	1.60	1.55–1.65	128347	1.67	1.60–1.75	28699	2.25	2.05–2.47
Individuals without diabetes prior to index
Average	240337	1.48	1.41–1.56	120828	1.71	1.6–1.82	27392	2.42	2.13–2.75
Individuals with diabetes prior to index
Average	14743	1.01	0.97–1.06	7519	0.95	0.90–1.01	1307	0.92	0.80–1.06

Table 3 Risk and Risk Difference of the Metabolic Risk Factors in Patients with Psoriasis Compared to Individuals Without Psoriasis in Six Months, One Year, Five Years and 10 Years After Dispensing Date

	Non Psoriasis		Psoriasis		Difference
	Risk	95% CI	Risk	95% CI	Risk	95% CI
Hypertension
Mild
Predicted risk at 6m	0.15	0.15–0.15	0.17	0.17–0.18	0.02	0.02–0.03
Predicted risk at 1y	0.18	0.18–0.18	0.22	0.21–0.22	0.04	0.03–0.04
Predicted risk at 5y	0.35	0.35–0.35	0.41	0.41–0.42	0.07	0.06–0.07
Predicted risk at 10y	0.50	0.50–0.50	0.57	0.57–0.58	0.07	0.07–0.08
Moderate
Predicted risk at 6m	0.16	0.15–0.16	0.18	0.18–0.19	0.03	0.02–0.03
Predicted risk at 1y	0.19	0.19–0.19	0.23	0.22–0.23	0.04	0.03–0.05
Predicted risk at 5y	0.36	0.35–0.36	0.44	0.43–0.44	0.08	0.07–0.09
Predicted risk at 10y	0.52	0.51–0.52	0.61	0.60–0.61	0.09	0.08–0.10
Severe
Predicted risk at 6m	0.11	0.11–0.12	0.15	0.14–0.17	0.04	0.03–0.05
Predicted risk at 1y	0.14	0.13–0.14	0.20	0.19–0.21	0.06	0.05–0.07
Predicted risk at 5y	0.27	0.27–0.28	0.40	0.39–0.41	0.13	0.12–0.14
Predicted risk at 10y	0.42	0.41–0.43	0.58	0.56–0.59	0.16	0.14–0.17
Hypercholesterolemia
Mild
Predicted risk at 6m	0.12	0.12–0.12	0.15	0.14–0.15	0.03	0.03–0.04
Predicted risk at 1y	0.13	0.13–0.14	0.17	0.17–0.18	0.04	0.04–0.04
Predicted risk at 5y	0.21	0.21–0.21	0.27	0.27–0.27	0.06	0.05–0.06
Predicted risk at 10y	0.29	0.29–0.29	0.36	0.35–0.37	0.07	0.06–0.07
Moderate
Predicted risk at 6m	0.12	0.12–0.12	0.14	0.14–0.15	0.02	0.02–0.03
Predicted risk at 1y	0.14	0.13–0.14	0.17	0.16–0.17	0.03	0.03–0.04
Predicted risk at 5y	0.22	0.21–0.22	0.27	0.27–0.28	0.06	0.05–0.06
Predicted risk at 10y	0.30	0.30–0.30	0.37	0.36–0.38	0.07	0.06–0.08
Severe
Predicted risk at 6m	0.08	0.08–0.09	0.10	0.09–0.11	0.02	0.01–0.03
Predicted risk at 1y	0.10	0.09–0.10	0.12	0.11–0.13	0.03	0.02–0.04
Predicted risk at 5y	0.16	0.15–0.16	0.22	0.21–0.24	0.07	0.06–0.08
Predicted risk at 10y	0.23	0.22–0.23	0.33	0.32–0.35	0.10	0.09–0.12
Diabetes
Mild
Predicted risk at 6m	0.03	0.03–0.03	0.04	0.04–0.05	0.02	0.01–0.02
Predicted risk at 1y	0.04	0.04–0.04	0.06	0.06–0.06	0.02	0.02–0.03
Predicted risk at 5y	0.08	0.08–0.08	0.13	0.13–0.14	0.05	0.05–0.05
Predicted risk at 10y	0.13	0.13–0.13	0.19	0.18–0.19	0.06	0.06–0.07
Moderate
Predicted risk at 6m	0.03	0.03–0.03	0.05	0.04–0.05	0.02	0.01–0.02
Predicted risk at 1y	0.04	0.04–0.04	0.06	0.06–0.07	0.02	0.02–0.03
Predicted risk at 5y	0.08	0.08–0.09	0.14	0.13–0.14	0.05	0.05–0.06
Predicted risk at 10y	0.13	0.13–0.13	0.20	0.2–0.21	0.07	0.06–0.08
Severe
Predicted risk at 6m	0.02	0.02–0.02	0.04	0.04–0.05	0.02	0.01–0.03
Predicted risk at 1y	0.03	0.03–0.03	0.06	0.05–0.07	0.03	0.02–0.04
Predicted risk at 5y	0.06	0.06–0.07	0.14	0.13–0.15	0.07	0.06–0.09
Predicted risk at 10y	0.11	0.10–0.11	0.21	0.20–0.23	0.11	0.09–0.12

Abbreviations: m, month; y, year.